热门出版物 - 学术资源搜索

h5 指数:49
h5 中位数:73

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#9 Medicinal Chemistry

标题/作者	引用次数	年份
Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018) A Nocentini, CT Supuran Expert Opinion on Therapeutic Patents 28 (10), 729-740	156	2018
Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011–2016) A Hameed, M Al-Rashida, M Uroos, SA Ali, Arshia, M Ishtiaq, KM Khan Expert Opinion on Therapeutic Patents 28 (4), 281-297	155	2018
Solid lipid nanoparticles: a review on recent perspectives and patents R Paliwal, SR Paliwal, R Kenwat, BD Kurmi, MK Sahu Expert Opinion on Therapeutic Patents 30 (3), 179-194	155	2020
Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas CT Supuran Expert Opinion on Therapeutic Patents 28 (10), 709-712	146	2018
A decade of nutraceutical patents: where are we now in 2018? P Daliu, A Santini, E Novellino Expert Opinion on Therapeutic Patents 28 (12), 875-882	127	2018
Sulfonamide inhibitors: a patent review 2013-present İ Gulçin, P Taslimi Expert Opinion on Therapeutic Patents 28 (7), 541-549	115	2018
Marine natural products as source of new drugs: a patent review (2015–2018) P Shinde, P Banerjee, A Mandhare Expert Opinion on Therapeutic Patents 29 (4), 283-309	109	2019
Multicomponent reactions (MCR) in medicinal chemistry: a patent review (2010-2020) HA Younus, M Al-Rashida, A Hameed, M Uroos, U Salar, S Rana, ... Expert Opinion on Therapeutic Patents 31 (3), 267-289	100	2021
MAO inhibitors and their wider applications: a patent review S Carradori, D Secci, JP Petzer Expert Opinion on Therapeutic Patents 28 (3), 211-226	98	2018
Bioactivity and pharmacological properties of α-mangostin from the mangosteen fruit: a review G Chen, Y Li, W Wang, L Deng Expert Opinion on Therapeutic Patents 28 (5), 415-427	97	2018
Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases CT Supuran Expert Opinion on Therapeutic Patents 28 (10), 713-721	97	2018
Benzoxaborole compounds for therapeutic uses: a patent review (2010-2018) A Nocentini, CT Supuran, JY Winum Expert Opinion on Therapeutic Patents 28 (6), 493-504	97	2018
A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018) S Shaabani, HPS Huizinga, R Butera, A Kouchi, K Guzik, ... Expert Opinion on Therapeutic Patents 28 (9), 665-678	95	2018
Biomedical applications of prokaryotic carbonic anhydrases CT Supuran, C Capasso Expert Opinion on Therapeutic Patents 28 (10), 745-754	94	2018
FAK inhibitors in Cancer, a patent review PC Lv, AQ Jiang, WM Zhang, HL Zhu Expert Opinion on Therapeutic Patents 28 (2), 139-145	91	2018
Indazole derivatives and their therapeutic applications: a patent review (2013-2017) I Denya, SF Malan, J Joubert Expert Opinion on Therapeutic Patents 28 (6), 441-453	88	2018
Saffron and its derivatives, crocin, crocetin and safranal: a patent review M Rameshrad, BM Razavi, H Hosseinzadeh Expert Opinion on Therapeutic Patents 28 (2), 147-165	88	2018
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19 I Vicenti, M Zazzi, F Saladini Expert Opinion on Therapeutic Patents 31 (4), 325-337	86	2021
A patent review of IDO1 inhibitors for cancer JE Cheong, A Ekkati, L Sun Expert Opinion on Therapeutic Patents 28 (4), 317-330	85	2018
Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018) K Haider, S Rahaman, MS Yar, A Kamal Expert Opinion on Therapeutic Patents 29 (8), 623-641	79	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。